Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia

✍ Scribed by Lancet, J E; Gojo, I; Burton, M; Quinn, M; Tighe, S M; Kersey, K; Zhong, Z; Albitar, M X; Bhalla, K; Hannah, A L

• Book ID: 109887047
• Publisher: Nature Publishing Group
• Year: 2010
• Tongue: English
• Weight: 337 KB
• Volume: 24
• Category: Article
• ISSN: 0887-6924
• DOI: 10.1038/leu.2009.292